Gene therapy and mRNA production tools

Our range of specialised research tools supports every stage of gene therapy and mRNA development, from high-efficiency cloning and library construction to reliable transfection and low-endotoxin reagents, helping researchers streamline workflows and achieve consistent results.

Why choose Cayman Chemical LNPs for your targeted delivery?

Cayman Chemical is a trusted partner for researchers developing genetic medicines, offering high-quality lipid nanoparticle (LNP) components and formulations to support nucleic acid delivery. Cayman’s portfolio includes ionisable lipids, phospholipids, cholesterol analogs, and PEG-lipids - all manufactured to exacting analytical standards. These lipids are designed to optimise encapsulation efficiency, protect mRNA from degradation, and ensure reliable delivery in gene therapy and vaccine research.

Benefits of using Cayman Chemical LNPs

• High-purity, validated lipid components for reproducible results
• Optimised for efficient mRNA and gene therapy delivery
• Scalable solutions suitable from discovery through preclinical research
• Custom formulation support available

Why choose Mirus Bio VirusGen for your viral vector production?

Mirus Bio’s VirusGen® platform delivers optimised solutions for scalable and efficient AAV and lentiviral vector production. With proprietary transfection reagents and protocols, VirusGen is designed to increase viral titers, improve consistency, and streamline the path from discovery through clinical research. Mirus combines decades of expertise in nucleic acid delivery with innovative chemistries to empower gene therapy development.

Benefits of using Mirus VirusGen

• High-titer, scalable AAV and lentiviral vector production
• Optimised transfection chemistry for reproducible performance
• Streamlined workflows from research to translational applications
• Flexible solutions adaptable to diverse gene therapy pipelines

Why choose KACTUS CRISPR enzymes for accurate gene editing?

KACTUS delivers high-performance CRISPR enzymes with exceptional activity, produced under both research-use and GMP-grade conditions. The KACTUS CRISPR Cas9 nuclease is a wild-type protein engineered to maximise ribonucleoprotein (RNP) editing efficiency across diverse cell types, including difficult-to-edit primary T cells. This makes it a powerful tool for advancing gene editing and therapeutic research.

Benefits of using KACTUS enzymes

• High activity and purity to ensure reliable, reproducible gene editing results
• GMP-grade manufacturing for long-term stability and regulatory alignment
• Scalable production with stringent quality control for batch-to-batch consistency
• Custom enzyme development tailored to specific project needs

Why choose Lucigen competent cells for reliable cloning and expression?

Lucigen offers a broad portfolio of high-efficiency competent cells optimised for molecular cloning, protein expression, and gene therapy applications. With specialised E. coli strains available as both chemically competent cells and electrocompetent cells, Lucigen enables researchers to tackle challenging cloning projects, build diverse libraries, and scale recombinant protein expression with confidence. Designed to address common bottlenecks such as low transformation efficiency, unstable plasmids, and endotoxin contamination, Lucigen competent cells deliver consistent results across research and therapeutic development.

Benefits of using Lucigen competent cells

• High transformation efficiency to improve cloning success rates
• Specialised strains for cloning large, unstable, or toxic plasmids
• Endotoxin-free options for gene therapy and protein production workflows
• Robust performance in phage display and CRISPR cloning applications